KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Receivables (2020 - 2025)

Esperion Therapeutics (ESPR) has disclosed Change in Receivables for 6 consecutive years, with $21.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 72.19% year-over-year to $21.2 million, compared with a TTM value of $60.0 million through Dec 2025, up 89.74%, and an annual FY2025 reading of $60.0 million, up 89.74% over the prior year.
  • Change in Receivables was $21.2 million for Q4 2025 at Esperion Therapeutics, up from $11.2 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $26.5 million in Q2 2025 and bottomed at -$144000.0 in Q3 2021.
  • Average Change in Receivables over 5 years is $6.4 million, with a median of $4.5 million recorded in 2021.
  • The sharpest move saw Change in Receivables plummeted 105.01% in 2021, then soared 2631.25% in 2022.
  • Year by year, Change in Receivables stood at $1.2 million in 2021, then skyrocketed by 83.01% to $2.2 million in 2022, then surged by 162.1% to $5.9 million in 2023, then surged by 109.81% to $12.3 million in 2024, then soared by 72.19% to $21.2 million in 2025.
  • Business Quant data shows Change in Receivables for ESPR at $21.2 million in Q4 2025, $11.2 million in Q3 2025, and $26.5 million in Q2 2025.